Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy
Immunotherapy does not seem to increase the risk of 30-day mortality in patients with COVID-19 infections compared to published outcomes of patients with cancer and COVID-19. Mortality was associated with certain clinical characteristics that need to be carefully examined when prescribing immunotherapy during future comparable pandemics.
Authors
- Jacques Raphael (ORCID: https://orcid.org/0000-0002-9484-0224)
- Phillip Blanchette (ORCID: https://orcid.org/0000-0001-8865-0996)
- Matthew C. Cheung (ORCID: https://orcid.org/0000-0003-3193-5872)
- Britney Le (ORCID: https://orcid.org/0000-0003-2655-0628)
- Maureen Trudeau (ORCID: https://orcid.org/0000-0002-0938-4499)
- Melody Lam (ORCID: https://orcid.org/0000-0001-6989-7926)
- Simron Singh (ORCID: https://orcid.org/0000-0002-5179-7043)
Institutions
- Western University (CA)
- Sunnybrook Health Science Centre (CA)
- Mount Vernon Cancer Centre (GB)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s12885-025-14318-2
- Citations
- 2
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 2.09